乙胺酰香豆 | 1233-70-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 中文名称: 乙胺酰香豆
• 中文别名: 地阿巴隆
• 英文名称: Diarbarone
• 英文别名: N-[2-(diethylamino)ethyl]-4-hydroxy-2-oxochromene-3-carboxamide
• CAS: 1233-70-1
• 化学式: C₁₆H₂₀N₂O₄
• 分子量: 304.346
• InChiKey: OGWJLWKFDHLZHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2924199090

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• THE FIVE CRYSTAL FORMS OF THE NICOUSAMIDE, THE PREPARATION METHODS, THE PHARMACEUTICAL COMPOSITIONS AND THE USES THEREOF
  申请人：Institute of Mataria Medica, Chinese Academy of Medical Sciences

  公开号：EP2361907A1

  公开（公告）日：2011-08-31

  This invention makes public that the five crystal forms of XLF-III-43 can be used as crude drugs, refers to the preparing methods of the five crystal forms of XLF-III-43 as crude drugs, refers to applying the sterling of the five crystal forms of XLF-III-43 and mixed crystals with different proportions as medicine active components to develop all kinds of medicines and compound medicines. In addition, this invention also refers to applying the crystal samples of XLF-III-43 as crude drugs to treat kidney dysfunction, cardiocerebral vessel diseases, hypertension, type II diabetic mellitus, complications of hypertension and diabetic mellitus, tumor, precancerosis, edema , and bring therapeutic effects by enhancing blood drug levels resulted from effects of crystal forms in the processes of treating all kinds of diseases.

  本发明公开了XLF-III-43的五种晶型可以作为粗制药物，提到了XLF-III-43的五种晶型作为粗制药物的制备方法，提到了应用XLF-III-43的五种晶型的立体和不同比例的混合晶型作为药物活性成分，开发各种药物和复方药物。此外，本发明还指将XLF-III-43的晶体样品作为原药，用于治疗肾功能不全、心脑血管疾病、高血压、Ⅱ型糖尿病、高血压和糖尿病并发症、肿瘤、癌前病变、水肿等，并在治疗各种疾病的过程中，通过提高晶体作用产生的血药浓度，发挥治疗作用。
• LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM
  申请人：St. Anna Kinderkrebsforschung

  公开号：EP3502130A1

  公开（公告）日：2019-06-26

  Disclosed is a ligand regulated protein-protein interaction system based on a lipocalin-fold molecule comprising: (a) a lipocalin-fold molecule (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below, and (c) a lipocalin-fold binding interaction partner, wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand, and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 µM to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.

  所公开的是一种基于脂钙蛋白折叠分子的配体调节蛋白质-蛋白质相互作用系统，该系统包括 (a) 脂钙蛋白折叠分子 (b) 低分子量为 1500 Da 或以下的脂钙蛋白-折叠配体，以及 (c) 脂钙蛋白-折叠结合相互作用伙伴、 其中脂钙素折叠分子可与脂钙素折叠配体结合；以及 其中与脂钙蛋白配体结合的脂钙蛋白-折叠分子与脂钙蛋白-折叠结合相互作用伙伴结合的亲和力比未与脂钙蛋白-折叠配体结合的脂钙蛋白-折叠分子的亲和力至少高 10 倍、 其中脂钙蛋白-折叠结合相互作用伙伴不是天然存在的蛋白质，它在任何脂钙蛋白-折叠配体存在下对任何天然存在的脂钙蛋白-折叠分子的亲和力小于10 µM。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13